FeRX tests MTC (Magnetic Targeted Carrier)-based gene therapy in Japan:
This article was originally published in Clinica
Executive Summary
FeRx has entered into a research agreement with Japan's National Cancer Center Research Institute (NCCRI) to develop a tumour-targeting gene transfer approach that uses FeRx's Magnetic Targeted Carrier (MTC) drug delivery technology. "An important goal of the collaboration will be improvement of the site specific delivery of genetic vectors to the disease site, one of the continuing development challenges facing gene therapy," said Dr Takahiro Ochiya of the NCCRI. MTC uses magnetic fields to target agents to specific areas in the body. The San Diego, California firm is already testing the method in the treatment of cancers (see Clinica No 1010, p 24).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.